These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 7181534)

  • 1. Cadmium modification of the response in Balb/c mice to MOPC-104E tumor.
    Gray I; Arrieh M; Balter NJ
    Arch Environ Health; 1982; 37(6):342-5. PubMed ID: 7181534
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effector and enhancing lymphoid cells in plasmacytoma-bearing mice. I. Methodological studies on the Winn assay.
    Wang KC; Berczi I; Sehon AH
    Int J Cancer; 1980 Apr; 25(4):487-92. PubMed ID: 7372372
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Some characteristics of the in vivo antitumor immunity exhibited by mice cured of a large MOPC-315 tumor by a low dose of melphalan.
    Barker E; Mokyr MB
    Cancer Immunol Immunother; 1987; 25(3):215-24. PubMed ID: 3677124
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction of tumor-specific antitumor immunity after chemotherapy with cisplatin in mice bearing MOPC-104E plasmacytoma by modulation of MHC expression on tumor surface.
    Nio Y; Hirahara N; Minari Y; Iguchi C; Yamasawa K; Toga T; Tamura K
    Anticancer Res; 2000; 20(5A):3293-9. PubMed ID: 11062756
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Surface immunoglobulins of lymphocytes in plasmacytoma. V. The effect of RNA-rich extract from mouse plasmacytoma MOPC 104E on the immune response.
    Bhoopalam N; Chen Y; Yakulis V; Heller P
    Clin Exp Immunol; 1976 May; 24(2):357-67. PubMed ID: 1277583
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction by cyclophosphamide administration of two distinct anti-tumor effector cells at tumor site and spleen of mice transplanted with MOPC-104E plasmacytoma.
    Nio Y; Ohgaki K; Tobe T
    J Clin Lab Immunol; 1989 May; 29(1):37-43. PubMed ID: 2534133
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulation of MOPC 104E by T cells and growth factors induced by C. parvum stimulation.
    Shrestha K; Hiramoto RN; Ghanta VK
    Int J Cancer; 1984 Jun; 33(6):845-50. PubMed ID: 6610653
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of plasmacytomas on serum immunoglobulin levels of BALB/c mice.
    Fenton MR; Havas HF
    J Immunol; 1975 Feb; 114(2 pt 2):793-801. PubMed ID: 1089719
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The allogeneic effect on tumor growth. II. Suppression of both ascitic and solid MOPC 315 plasmacytoma by the graft-vs-host reaction, with pathologic correlation.
    Osborne DP; Katz DH
    J Immunol; 1977 Apr; 118(4):1449-55. PubMed ID: 15035
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Appearance of a variant of MOPC 104E which does not react with dextran B-1355s.
    Folds JD
    Immunol Commun; 1977; 6(4):385-94. PubMed ID: 407151
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of growth of MOPC 104E cells in immunosuppressed mice.
    Hiramoto RN; Cox PJ; Hiramoto NS; Ghanta VK
    J Immunol; 1984 Dec; 133(6):3424-8. PubMed ID: 6386985
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunity against MOPC 104E plasmacytoma: effects of tumor size and time post therapy on in vivo tumor immunity.
    Lubet RA; Carlson DE
    J Natl Cancer Inst; 1978 May; 60(5):1107-11. PubMed ID: 642029
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapy of the murine plasmacytoma MOPC 104E: role of the immune response.
    Lubet RA; Carlson DE
    J Natl Cancer Inst; 1978 Sep; 61(3):897-903. PubMed ID: 278867
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of immune response to sheep red blood cells on plasmacytoma MOPC 104 E.
    Ghanta VK; Hiramoto NS; Hiramoto RN
    Cancer Res; 1981 Jun; 41(6):2197-9. PubMed ID: 7237419
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of resistance to MOPC-315 plasmacytoma after intralesional and intraperitoneal melphalan therapy of tumor-bearing BALB/c mice. I. Enhancement of in vivo rejection responses by combined chemotherapy-immunotherapy.
    Adler A; Altbaum I
    J Natl Cancer Inst; 1982 Jun; 68(6):963-9. PubMed ID: 6953275
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro effect of monoclonal anti-idiotype antibodies (anti-M104E) on MOPC 104E myeloma cells.
    Kodama K; Ghanta VK; Hiramoto RN; Stohrer RC; Kearney JF
    Cancer Res; 1986 Mar; 46(3):1250-4. PubMed ID: 3484677
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantitation of total-body tumor cells (MOPC 104E). I. Subcutaneous tumor model.
    Ghanta VK; Hiramoto RN
    J Natl Cancer Inst; 1974 Apr; 52(4):1199-202. PubMed ID: 4826588
    [No Abstract]   [Full Text] [Related]  

  • 18. Quantitation of total-body tumor cells (MOPC 104E). II. Ascites tumor model.
    Hiramoto RN; Ghanta VK; Hamlin NM
    J Natl Cancer Inst; 1974 Sep; 53(3):767-71. PubMed ID: 4415421
    [No Abstract]   [Full Text] [Related]  

  • 19. Importance of tumor-specific cytotoxic CD8+ T-cells in eradication of a large subcutaneous MOPC-315 tumor following low-dose melphalan therapy.
    Takesue BY; Pyle JM; Mokyr MB
    Cancer Res; 1990 Dec; 50(23):7641-9. PubMed ID: 2123740
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effector and enhancing lymphoid cells in plasmacytoma-bearing mice. II. Dynamic changes during tumor progression.
    Wang WC; Berczi I; Hoffmann EG; Sehon AH
    Int J Cancer; 1980 Apr; 25(4):493-501. PubMed ID: 6246008
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.